Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Age-Related Macular Degeneration Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for age-related macular degeneration has experienced robust expansion lately, with projections indicating continued growth from $10.67 billion in 2025 to $11.46 billion in 2026, reflecting a compound annual growth rate of 7.5%. Factors contributing to this historical upward trend include an aging global demographic, the increasing incidence of AMD, a scarcity of treatment alternatives in earlier times, heightened public consciousness regarding eye health, and the enhancement of healthcare facilities, specifically hospitals and ophthalmology clinics.
The market for age-related macular degeneration is poised for substantial expansion in the coming years, projected to reach $15.42 billion by 2030, driven by a compound annual growth rate of 7.7%. This anticipated growth stems from advancements in next-generation anti-VEGF medications, increased investment in ophthalmology research, the proliferation of specialty and online pharmacies, the growing application of combination therapies, and a rising preference for personalized treatment strategies. Key developments anticipated during this forecast period encompass a greater uptake of anti-VEGF therapies, increased utilization of nutritional supplements and low vision aids, an uptick in photodynamic and laser therapy procedures, the broadening of intravitreal and intravenous administration methods, and a heightened emphasis on public awareness campaigns coupled with routine eye examinations.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp
Age-Related Macular Degeneration Market Industry Drivers: What Is Driving Revenue Growth?
The increasing incidence of age-related macular degeneration (AMD) is anticipated to be a significant catalyst for the expansion of the AMD market in the coming years. AMD, a condition characterized by gradual deterioration of the macula, the central part of the retina crucial for sharp vision, impacts numerous individuals. Therapies for AMD aim to alleviate the suffering of those with retinal conditions by mitigating the adverse effects of the disease. Evidence from Optimaxa, a UK-based expert in laser eye treatments, indicated in February 2023 that approximately 196 million people worldwide were affected by AMD, with projections suggesting this number could climb to 288 million by 2040, representing 8.7% of the global populace. Consequently, the growing prevalence of AMD is directly fueling the growth of its market.
Age-Related Macular Degeneration Market Segment Performance And Strategic Opportunities
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Drugs
3) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
#Age-Related Macular Degeneration Market Growth Trends: What Is Influencing The Future Outlook?
Within the market for age-related macular degeneration (AMD), leading corporations are spearheading the development of pioneering solutions, including recombinant antigen-binding fragments. These engineered proteins, known as recombinant Fab fragments, originate from antibodies designed for precise antigen interaction and are frequently employed therapeutically to impede disease progression. Specifically, in December of 2023, Enzene Biosciences, a biotechnology firm situated in India, introduced ranibizumab. This ranibizumab is a recombinant monoclonal antibody fragment (Fab) meticulously crafted to neutralize vascular endothelial growth factor (VEGF), a critical protein implicated in the aberrant blood vessel formation characteristic of conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). Through the inhibition of VEGF, ranibizumab effectively mitigates the leakage and growth of these abnormal vessels, thereby safeguarding vision for individuals affected by these retinal afflictions. Administered via intravitreal injection, its effectiveness in managing a spectrum of retinal diseases has led to its broad adoption in clinical settings. The availability of ranibizumab represents a significant advancement in the therapeutic options for individuals confronting these severe visual impairments.
Age-Related Macular Degeneration Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Outlook Therapeutics Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.
Access The Complete Age-Related Macular Degeneration Market Report:
Age-Related Macular Degeneration Market Largest Region By Revenue And Market Share
North Americawas the largest region in the global age-related macular degeneration market in 2025.Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
